Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Growth Hormones (Nov 2018)

Posted by Matt Breese on Nov 30, 2018

Find me on:

According to our recent payer coverage analysis for growth hormone treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for growth hormone treatments shows that more than 60% of covered lives under the pharmacy benefit in commercial formularies and health exchange programs have some type of utilization management restriction.

MMIT-Reality Check-GrowthHormones_4Q2018Data snapshot as of Q4 2018

Trends: The market is trending toward the development of long-acting growth hormone drugs that can be administered weekly or biweekly instead of currently marketed daily growth hormones. Via AIS Health.

To read the full Reality Check on Growth Hormone treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


                                                    View Reality Check


Topics: Specialty, Market Access, Payer, Branding & Marketing